Philips provides update on the Annual General Meeting of Shareholders 2025 Agenda
Philips (NYSE: PHG) has provided an update regarding its upcoming Annual General Meeting (AGM) scheduled for March 24, 2025. The key focus is on the appointment of Bob White to the Supervisory Board, effective May 8, 2025.
Following White's nomination as CEO at Olympus , there has been a modification to his planned role at Philips. While he will still join the Quality & Regulatory (Q&R) Committee, he will no longer serve as its chair. Dr Paul Stoffels will instead chair the Q&R Committee, while Herna Verhagen will succeed Stoffels as chair of the Remuneration Committee.
White's dual positions at Philips and Olympus will align with proxy advisor guidelines, consisting of one non-executive and one executive position at publicly listed companies.
Philips (NYSE: PHG) ha fornito un aggiornamento riguardo alla sua prossima Assemblea Generale Annuale (AGM) prevista per il 24 marzo 2025. Il punto centrale riguarda la nomina di Bob White nel Consiglio di Sorveglianza, con effetto dal 8 maggio 2025.
A seguito della nomina di White a CEO di Olympus, è stata modificata la sua posizione prevista in Philips. Pur entrando nel Comitato Qualità e Regolamentazione (Q&R), non ne sarà più il presidente. Dr Paul Stoffels assumerà la presidenza del Comitato Q&R, mentre Herna Verhagen succederà a Stoffels come presidente del Comitato Retribuzioni.
Le posizioni simultanee di White in Philips e Olympus rispetteranno le linee guida dei consulenti proxy, prevedendo un ruolo non esecutivo e uno esecutivo in società quotate.
Philips (NYSE: PHG) ha proporcionado una actualización sobre su próxima Junta General Anual (AGM) programada para el 24 de marzo de 2025. El enfoque principal es el nombramiento de Bob White en el Consejo de Supervisión, efectivo desde el 8 de mayo de 2025.
Tras la nominación de White como CEO de Olympus, se modificó su rol previsto en Philips. Aunque seguirá formando parte del Comité de Calidad y Regulación (Q&R), ya no será su presidente. Dr Paul Stoffels asumirá la presidencia del Comité Q&R, mientras que Herna Verhagen sucederá a Stoffels como presidenta del Comité de Remuneraciones.
Las posiciones duales de White en Philips y Olympus cumplirán con las directrices de los asesores de voto, consistiendo en un puesto no ejecutivo y otro ejecutivo en empresas cotizadas.
필립스 (NYSE: PHG)는 2025년 3월 24일 예정된 연례 주주총회(AGM)에 관한 최신 정보를 제공했습니다. 주요 내용은 밥 화이트가 2025년 5월 8일부로 감독위원회에 임명된다는 점입니다.
화이트가 올림푸스의 CEO로 지명된 이후 필립스에서 예정되었던 역할에 변경이 있었습니다. 그는 품질 및 규제(Q&R) 위원회에 계속 참여하지만, 위원장직은 맡지 않습니다. 대신 폴 스토펠스 박사가 Q&R 위원회의 의장을 맡으며, 헤르나 베르하겐이 스토펠스의 뒤를 이어 보수위원회의 의장이 됩니다.
화이트의 필립스와 올림푸스에서의 이중 직책은 공개 상장 기업에서 비집행 임원 한 자리와 집행 임원 한 자리를 갖도록 하는 의결권 자문 지침을 준수합니다.
Philips (NYSE : PHG) a communiqué une mise à jour concernant sa prochaine Assemblée Générale Annuelle (AGM) prévue pour le 24 mars 2025. Le point clé porte sur la nomination de Bob White au Conseil de Surveillance, effective à partir du 8 mai 2025.
Suite à la nomination de White en tant que CEO d'Olympus, son rôle prévu chez Philips a été modifié. Il rejoindra toujours le Comité Qualité & Réglementation (Q&R), mais n'en sera plus le président. Dr Paul Stoffels présidera désormais le comité Q&R, tandis que Herna Verhagen succédera à Stoffels en tant que présidente du Comité des Rémunérations.
Les fonctions doubles de White chez Philips et Olympus respecteront les directives des conseillers en vote, comprenant un poste non exécutif et un poste exécutif dans des sociétés cotées.
Philips (NYSE: PHG) hat ein Update zu seiner bevorstehenden Hauptversammlung (AGM) am 24. März 2025 veröffentlicht. Der Schwerpunkt liegt auf der Ernennung von Bob White in den Aufsichtsrat, wirksam ab dem 8. Mai 2025.
Nach Whites Ernennung zum CEO bei Olympus wurde seine geplante Rolle bei Philips angepasst. Er wird weiterhin dem Qualitäts- und Regulierungsausschuss (Q&R) angehören, jedoch nicht mehr dessen Vorsitz übernehmen. Stattdessen wird Dr. Paul Stoffels den Vorsitz des Q&R-Ausschusses übernehmen, während Herna Verhagen Stoffels als Vorsitzende des Vergütungsausschusses ablösen wird.
Whites Doppelfunktion bei Philips und Olympus entspricht den Richtlinien der Stimmrechtsberater und umfasst eine nicht-exekutive und eine exekutive Position bei börsennotierten Unternehmen.
- Appointment of experienced health technology executive Bob White to Supervisory Board
- Maintenance of strong corporate governance with immediate committee chair replacements
- Modification of planned leadership structure for Q&R Committee due to White's competing commitments
April 25, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) provides an update on the Annual General Meeting 2025 which has been convened on March 24, 2025 (AGM).
As previously announced, the AGM agenda includes the proposal to appoint Mr Bob White (American, 1962) as a new member of the Supervisory Board, with effect from May 8, 2025, given his extensive expertise and experience in health technology and quality.
Since the company published the agenda for the AGM, Mr White has been nominated to become Chief Executive Officer at Olympus Corporation and has informed the company that in view of this nomination and his nomination at Philips, he will step down from other board positions he currently holds.
In light hereof, the Supervisory Board and Mr White have agreed that he will become a member of Philips’ Quality & Regulatory (Q&R) Committee but that he will not be acting as its chair as was previously communicated.
Following shareholders’ approval of all proposals in respect of the Supervisory Board composition at the AGM, Dr Paul Stoffels will become chair of the Q&R Committee of the Supervisory Board, and Mrs Herna Verhagen will succeed Dr Paul Stoffels as chair of its Remuneration Committee.
Following his appointments at Philips and Olympus, Mr White will hold one non-executive and one executive position at publicly listed companies in line with current guidelines from proxy advisors on directors’ external commitments.
For further information, please contact:
Michael Fuchs
Philips Global External Relations
Tel.: +31 61486 9261
E-mail: media@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Forward-looking statements and other important information
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
FAQ
When is Philips (PHG) holding its Annual General Meeting 2025?
Who is being appointed to Philips' (PHG) Supervisory Board in 2025?
What changes were made to Bob White's role on Philips' (PHG) committees?
Who will chair Philips' (PHG) Quality & Regulatory Committee after the 2025 AGM?
